ClinicalTrials.gov
ClinicalTrials.gov Menu

Newborn Screening for Spinal Muscular Atrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02123186
Recruitment Status : Completed
First Posted : April 25, 2014
Last Update Posted : November 2, 2016
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:
To test if the routine newborn screening dried blood spots can be used to test if missing 2 copies of SMN1 gene, a status indicating spinal muscular atrophy

Condition or disease Intervention/treatment
Spinal Muscular Atrophy Other: newborn screening test for SMA

Detailed Description:
Parents of newborns will be invited to test if their newborns are affected with SMA. The routine newborn screening dried blood spots sample will be used to test if missing 2 copies of SMN1 gene. If positive of screening test, further confirmation tests including physical examination and other methology for SMN1 gene copies quantification will be provided. Genetic counseling and treatment option will be provided, too.

Study Type : Observational
Actual Enrollment : 120267 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Newborn Screening for Spinal Muscular Atrophy
Study Start Date : October 2013
Actual Primary Completion Date : October 2016
Actual Study Completion Date : October 2016


Group/Cohort Intervention/treatment
newborns testing for SMA Other: newborn screening test for SMA
Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.



Primary Outcome Measures :
  1. numbers of newborn with spinal muscular atrophy [ Time Frame: 18 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 3 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
newborns whose parents agree to be tested
Criteria

Inclusion Criteria:

  • Babies born in Taiwan receive regular new born screening suggested by Ministry of Heath and Welfare.
  • Parents or Legal Guardian sign in the informed consent form.

Exclusion Criteria:

  • Parents or Legal Guardian do not agree to sign in the informed consent form.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02123186


Locations
Taiwan
National Taiwan University Hospital
Taipei, Taiwan,, Taiwan, 100
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Yin-Hsiu Chien, M.D., PhD. National Taiwan University Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT02123186     History of Changes
Other Study ID Numbers: 201308058RIND
First Posted: April 25, 2014    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: April 2016

Keywords provided by National Taiwan University Hospital:
Newborn Screening , spinal muscular atrophy

Additional relevant MeSH terms:
Atrophy
Muscular Atrophy
Muscular Atrophy, Spinal
Pathological Conditions, Anatomical
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Spinal Cord Diseases
Central Nervous System Diseases
Motor Neuron Disease
Neurodegenerative Diseases
Neuromuscular Diseases